Revlimid 5 mg Capsules Special Use-results Surveillance of Transformation to Acute Myeloid Leukemia
Latest Information Update: 16 Jun 2022
At a glance
- Drugs Lenalidomide (Primary)
- Indications Acute myeloid leukaemia; Myelodysplastic syndromes
- Focus Adverse reactions
- Sponsors Celgene Corporation
- 13 Jun 2022 Status changed from active, no longer recruiting to completed.
- 27 May 2020 Planned End Date changed from 31 Dec 2019 to 19 Jun 2020.
- 27 May 2020 Planned primary completion date changed from 31 Dec 2019 to 19 Jun 2020.